Eli Lilly (LLY) wins US approval for Foundayo weight-loss drug
Published on Β· Source: ft.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) received US approval for its weight-loss drug, Foundayo. This approval introduces competition in the oral obesity drug market, particularly against Novo Nordisk. The specifics of the approval, including safety and efficacy data, have not been disclosed in this article. The entry of Foundayo may influence market dynamics as both companies vie for market share in the oral obesity treatment space.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) Receives FDA Approval for Obesity Pill
- Eli Lilly (LLY) GLP-1 Pill Approved: Launching Foundayo for Weight Loss
- Lilly (LLY) Wins FDA Approval for Oral Obesity Drug Foundayo
- Eli Lilly (LLY) stock surges after FDA obesity pill approval
- Lilly (LLY) to Acquire Centessa for OX2R Sleep Disorders
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
